Company

ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies to address cancer resistance.

About

Founded in 2014 and based in San Francisco, US, ORIC Pharmaceuticals was founded by Richard Heyman, Charles Sawyers, and Scott Lowe. As of 2024 its CEO is Jacob Chacko. Its pipeline includes ORIC-114, an orally bioavailable EGFR and HER2 inhibitor, ORIC-944, which targets the PRC2 complex, and ORIC-533, a CD73 inhibitor. In January 2024 the company raised USD 125 million in PIPE funding from Viking Global Investors, New Enterprise Associates, and Commodore Capital. Its listed stage is Public.

5Funding rounds

16Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in